← All candidates
One insider buy in the last year — $2.8K in all.
10 filings on record.
VIVSVivoSim Labs, INC.
NasdaqCM · Healthcare · $3.46M
$0.2700
-3.57% · Sep 15
One insider buy in the last year — $2.8K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 1 buy● 1 sell◆ 4 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 2×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what VIVS ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$3.46M
Float
14.4M
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
30.9
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Chief Commercial Officer
Lialin Tony Serge
Bought $2.8K on Aug 31 — 10,000 sh @ $0.2804, held direct, 100% of their stake.
First Form 4 on file
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
1 filingnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
2 more transactions on Pro →Context
Coverage
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)InvestorsHub · 07-21VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue GrowthInvestorsHub · 07-15NIO January Deliveries Nearly Double Year On YearGuruFocus.com · 02-02Top Midday GainersMT Newswires · 01-30
The file stays open
10 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice